BALTIMORE — Lupin announced the appointment of Nicholas (Nick) Hart as president – specialty for its U.S. business. Hart will lead the specialty strategic business unit in the United States and will be responsible for Lupin’s specialty brand business growth strategy, P&L and organization.

Nick Hart

Hart brings over 25 years of specialty business, strategic and commercial operations experience to Lupin. He has led the launch of numerous products both globally and in the U.S. in multiple therapeutic areas, including Women’s Health. Most recently, he was the business unit head for reproductive health at Ferring Pharmaceuticals, Inc.

Prior to Ferring, Hart served as senior vice president of sales and marketing at URL Pharma. He has strong experience in the pharmaceutical industry in both specialty pharma and big pharma, and has held positions of increasing responsibility in commercial operations, corporate strategy and business development.  

Commenting on the appointment, Vinita Gupta, chief executive officer, Lupin said, “We are delighted to welcome Nick to Lupin at a crucial time as we prepare to launch Solosec in the US market and accelerate efforts to build our Specialty business.  His knowledge and experience in the industry will be valuable for our growth aspirations in the US market.”

He will be based in Baltimore, Md. and will report to Vinita Gupta.